Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc.
Your view on MEDXF
Overview
What the company does, where it operates, and who runs it.
About Medexus Pharmaceuticals Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Kenneth d'Entremont
- Headquarters
- 35 Nixon Road, Bolton, ON, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Kenneth d'Entremont
- Headquarters
- 35 Nixon Road, Bolton, ON, CA
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy.
The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.
Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms.
The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Medexus Pharmaceuticals Inc., and the rating behind it. MEDXF last traded at $2.11; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Medexus Pharmaceuticals Inc.. Starting points for Medexus Pharmaceuticals Inc.: EPS -$0.07, beta 1.98 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Medexus Pharmaceuticals Inc.. Medexus Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Medexus Pharmaceuticals Inc.. Trailing twelve-month EPS for Medexus Pharmaceuticals Inc. stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Medexus Pharmaceuticals Inc.. Medexus Pharmaceuticals Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Medexus Pharmaceuticals Inc. valued side by side against its closest peers. Medexus Pharmaceuticals Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Medexus Pharmaceuticals Inc., and how their positions are changing. At a $68.2M market value, institutional positions materially move Medexus Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Medexus Pharmaceuticals Inc. executives and directors. Shares of Medexus Pharmaceuticals Inc. have traded between $1.43 and $2.62 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Medexus Pharmaceuticals Inc.. Medexus Pharmaceuticals Inc. is a $68.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Medexus Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Medexus Pharmaceuticals Inc.. Coverage tracks Medexus Pharmaceuticals Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.